Total Payments
$4,652
2024 Payments
$543.63
Companies
44
Transactions
123
Medicare Patients
30,445
Medicare Billing
$9.5M
Payment Breakdown by Category
Food & Beverage$2,405 (51.7%)
Research$1,844 (39.6%)
Education$402.84 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,405 | 96 | 51.7% |
| Unspecified | $1,844 | 3 | 39.6% |
| Education | $402.84 | 24 | 8.7% |
Payments by Type
General
$2,808
120 transactions
Research
$1,844
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1,844 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $244.50 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $225.45 | 7 | $0 (2024) |
| PFIZER INC. | $210.53 | 13 | $0 (2024) |
| Exelixis Inc. | $191.99 | 12 | $0 (2018) |
| Gilead Sciences, Inc. | $174.26 | 4 | $0 (2023) |
| Allergan, Inc. | $166.27 | 7 | $0 (2021) |
| Pharmacyclics LLC, an AbbVie Company | $125.83 | 2 | $0 (2022) |
| Seagen Inc. | $117.01 | 6 | $0 (2023) |
| TESARO, Inc. | $103.15 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $543.63 | 28 | Daiichi Sankyo Inc. ($81.43) |
| 2023 | $345.77 | 18 | PFIZER INC. ($79.02) |
| 2022 | $308.28 | 14 | Pharmacyclics LLC, an AbbVie Company ($105.00) |
| 2021 | $380.83 | 16 | Daiichi Sankyo Inc. ($123.73) |
| 2020 | $309.89 | 15 | Allergan, Inc. ($100.46) |
| 2019 | $307.85 | 6 | Gilead Sciences, Inc. ($124.87) |
| 2018 | $1,738 | 9 | Eli Lilly and Company ($1,588) |
| 2017 | $718.40 | 17 | Eli Lilly and Company ($256.66) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 2 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: GENETIC DISEASE | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Oncology | ||||||
| 01/06/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $14.17 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: ONC | ||||||
| 10/30/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Genetic Disease | ||||||
| 10/23/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: SURGERY | ||||||
| 08/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: Oncology | ||||||
| 08/04/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.50 | General |
| 06/09/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Oncology | ||||||
| 05/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: GENETIC DISEASE | ||||||
| 05/09/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Oncology | ||||||
| 04/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.92 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2022 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Oncology | ||||||
| 11/16/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.64 | General |
| Category: Oncology | ||||||
| 09/09/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Oncology | ||||||
| 07/28/2022 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | Eli Lilly and Company | $1,844 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 88 | 7,146 | 173,646 | $7.8M | $2.2M |
| 2022 | 90 | 7,037 | 152,975 | $7.5M | $2.1M |
| 2021 | 97 | 8,089 | 172,365 | $8.4M | $2.6M |
| 2020 | 99 | 8,173 | 192,204 | $8.2M | $2.5M |
Total Patients
30,445
Total Services
691,190
Medicare Billing
$9.5M
Procedure Codes
374
All Medicare Procedures & Services
374 procedure records from CMS Medicare Utilization — Page 15 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 34 | 52 | $2,600 | $608.05 | 23.4% |
| 82565 | Blood creatinine level | Office | 2020 | 91 | 119 | $2,023 | $586.17 | 29.0% |
| 88184 | Flow cytometry technique for dna or cell analysis | Office | 2020 | 12 | 12 | $1,992 | $581.52 | 29.2% |
| 83550 | Iron binding capacity | Office | 2020 | 36 | 59 | $1,770 | $512.43 | 29.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 246 | 4,816 | $4,816 | $471.97 | 9.8% |
| 71046 | X-ray of chest, 2 views | Office | 2020 | 24 | 33 | $5,412 | $456.92 | 8.4% |
| 36591 | Collection of blood specimen from a completely implantable venous access device | Office | 2020 | 16 | 25 | $1,300 | $453.25 | 34.9% |
| 82232 | Beta-2 microglobulin (protein) level | Office | 2020 | 17 | 25 | $1,375 | $401.94 | 29.2% |
| 83540 | Iron level | Office | 2020 | 36 | 61 | $1,159 | $392.20 | 33.8% |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | Office | 2020 | 21 | 263 | $3,682 | $392.09 | 10.6% |
| 90756 | Vaccine for influenza for injection into muscle | Office | 2020 | 12 | 12 | $804.00 | $332.40 | 41.3% |
| 36593 | Declotting infusion of implanted central venous access device or catheter | Office | 2020 | 11 | 12 | $828.00 | $274.76 | 33.2% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2020 | 33 | 43 | $688.00 | $266.69 | 38.8% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2020 | 84 | 126 | $1,012 | $255.00 | 25.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 15 | 15 | $783.00 | $236.70 | 30.2% |
| 85610 | Blood test, clotting time | Office | 2020 | 22 | 36 | $468.00 | $153.45 | 32.8% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2020 | 16 | 21 | $252.00 | $105.74 | 42.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2020 | 86 | 124 | $194.00 | $76.01 | 39.2% |
| 85045 | Red blood count, automated test | Office | 2020 | 17 | 17 | $238.00 | $67.11 | 28.2% |
| J3490 | Unclassified drugs | Office | 2020 | 73 | 99 | $838.00 | $65.76 | 7.8% |
| J0461 | Injection, atropine sulfate, 0.01 mg | Office | 2020 | 16 | 1,000 | $1,000 | $62.06 | 6.2% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2020 | 54 | 592 | $1,184 | $42.09 | 3.6% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2020 | 25 | 90 | $270.00 | $40.46 | 15.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2020 | 18 | 26 | $312.00 | $35.43 | 11.4% |
About Dr. Mark Olsen, M.D
Dr. Mark Olsen, M.D is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356382592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Olsen, M.D has received a total of $4,652 in payments from pharmaceutical and medical device companies, with $543.63 received in 2024. These payments were reported across 123 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($2,405).
As a Medicare-enrolled provider, Olsen has provided services to 30,445 Medicare beneficiaries, totaling 691,190 services with total Medicare billing of $9.5M. Data is available for 4 years (2020–2023), covering 374 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/09/2006
- Last Updated 05/08/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356382592
Products in Payments
- OPDIVO (Biological) $208.57
- Cabometyx (Drug) $191.99
- Enhertu (Drug) $151.04
- IBRANCE (Drug) $150.18
- Zydelig (Drug) $124.87
- IMBRUVICA (Drug) $105.00
- VARUBI (Drug) $103.15
- Optune (Device) $101.25
- INJECTAFER (Drug) $93.46
- PADCEV (Biological) $90.02
- XPOVIO (Drug) $82.49
- STRATTICE (Device) $76.31
- ADCETRIS (Biological) $66.16
- ZYTIGA (Drug) $63.99
- LIBTAYO (Biological) $59.80
- INQOVI (Drug) $51.16
- Lenvima (Drug) $45.79
- REBLOZYL (Biological) $41.78
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS (Device) $40.41
- BRUKINSA (Drug) $40.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488
Dr. Kevin Weibel, D.o, D.O
Hematology & Oncology — Payments: $4,174
Hematology & Oncology $4,174